Technology
Health
Pharmaceutical

Akcea Therapeutics

$20.68
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.05 (-4.83%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell AKCA and other stocks, options, ETFs, and crypto commission-free!

About

Akcea Therapeutics, Inc. engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. Read More It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA.

Employees
248
Headquarters
Boston, Massachusetts
Founded
2014
Market Cap
1.92B
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
270.55K
High Today
$21.44
Low Today
$20.62
Open Price
$21.32
Volume
111.54K
52 Week High
$40.75
52 Week Low
$20.62

Collections

Technology
Health
Pharmaceutical
Therapy
Advertising and Marketing
Business Services
2017 IPO
US

News

Seeking AlphaMay 9

Akcea Therapeutics, Inc. (AKCA) CEO Paula Soteropoulos on Q1 2019 Results - Earnings Call Transcript

Akcea Therapeutics, Inc. (NASDAQ:AKCA) Q1 2019 Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Kathleen Gallagher - Vice President of Corporate Communications & Investor Relations Paula Soteropoulos - Chief Executive Officer Sarah Boyce - President Michael MacLean - Chief Financial Officer Conference Call Participants Paul Matteis - Stifel Chad Messer - Needham Do Kim - BMO Capital Markets Subbu Nambi - Cowen Operator Good afternoon and welcome to your Akcea Therapeutics Fir...

78
Yahoo FinanceMay 8

Akcea Therapeutics Q1 Earnings and Revenues Lag Estimates

MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 7.69% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

10
Yahoo FinanceMay 1

Akcea Therapeutics (AKCA) Earnings Expected to Grow: Should You Buy?

Akcea Therapeutics (AKCA) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2019. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

150

Earnings

-$1.24
-$0.50
$0.24
$0.98
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
$0.98 per share
Actual
$0.67 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.